Business news with perspective

Cavvy Energy's stunning Q2 results are more than a commodity boom. A closer look reveals a story of strategic resilience and a powerful midstream pivot.

InfiMaker's new K1 desktop CNC combines true 5-axis machining with AI software, aiming to disrupt manufacturing. But can it deliver on its Kickstarter promise?

A traditional construction firm is set to become a pure-play AI robotics company on the NYSE. Why is JFB betting it all on XTEND's autonomous technology?

MetalCloak launches a new Tacoma suspension lineup, moving beyond simple lifts to offer three distinct, engineered systems for every type of owner.

COSCIENS Biopharma boasts a dramatic financial turnaround, but its strategic move to exit SEC oversight shifts the risk-reward calculus for investors.

As students face a choice between their health and education, one foundation offers direct aid. But does this agile approach mask a deeper systemic failure?

With new HKEX rules mandating rigorous board reviews, companies are at a crossroads. Specialist firms like GreenCo offer a path beyond compliance.

RBC and BMO's $2 billion sale of Moneris isn't just a big payday. It's a strategic retreat from a complex market, fueling a new chapter for Canadian commerce.

Aardvark Therapeutics faces a pivotal moment as an FDA clinical hold halts its lead drug trial, leaving the Prader-Willi Syndrome community waiting.

Jatagan Security's new UL Solutions verification for its reporting process could finally bring clarity to an industry plagued by unsubstantiated claims.

CanNor's latest funding is not just about infrastructure; it's a strategic play on Indigenous-led economic sovereignty and the future of Canada's North.

Shareholders have approved Fairfax Financial's buyout of Andrew Peller Ltd., ending its public chapter. This isn't just a deal; it's a strategic uncorking.

Reed's Q2 results show major operational gains and a shrinking net loss, but a steep sales decline and a looming cash crunch raise critical questions.

With a NYSE delisting notice and a dividend under scrutiny, Lument Finance Trust's Q2 report is more than just numbers—it's a test of its strategy.

SINTX Technologies is shifting from R&D to sales, but its ambitious med-tech goals are balanced by a precarious financial reality. Is this a blueprint for resilience?

With FDA clearance for its AI burn scanner, Spectral AI faces its next test: conquering the market. Can it turn government contracts into commercial success?

BridgeBio Oncology is doubling down on a costly strategy, betting that combining its novel drugs is the key to defeating hard-to-treat RAS-driven cancers.

Black Rock Coffee Bar reports a stellar quarter with 25% revenue growth, but a deeper look reveals the complex challenges of rapid expansion in a competitive market.

NeuroPace reports strong Q2 growth and raises 2026 guidance, driven by its RNS system. A new AI tool and key clinical data signal a deeper push into personalized medicine.

With pivotal data imminent for two cancer drugs and a fortified balance sheet, SELLAS is at a crucial inflection point. Can it deliver on its promise?